Phaseline

Companies › Qilu Pharmaceutical

Qilu Pharmaceutical: clinical trials, targets and expected readouts

29 active drug programs in 93 registered trials: 30 Phase 3, 29 Phase 2, 25 Phase 1, 9 Phase 4; Oncology, Immunology, Infectious disease, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tafamidis
Transthyretin stabiliser
TTRPhase 4Transthyretin Amyloid Polyneuropathy; Transthyretin Cardiac AmyloidosisJan 2028
Relugolix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Heavy Menstrual Bleeding; Cervical Mucus; Endometriosis; Recurrent Prostate Carcinoma …Nov 2026
QLC5508
B7H3-targeting antibody-drug conjugate
B7H3Phase 3Esophageal Squamous Cell Carcinoma (ESCC); Extensive-stage Small Cell Lung Cancer; Refractory or Relapsed Solid Tumors; Advanced Prostate Cancer …Dec 2026
Meropenem
Bacterial penicillin-binding protein inhibitor
FTSZPhase 3Hospital-acquired Bacterial Pneumonia (HABP); Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia; MDR Bacteria; Febrile Neutropenia …Dec 2026
Pembrolizumab (QL2107)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3NSCLC; Carcinoma, Non-Small-Cell Lung; Extensive-stage Small Cell Lung Cancer; Advanced Solid TumorDec 2026
QLM1016–Phase 3SchizophreniaDec 2026
Denosumab (QL1206)
Tumor necrosis factor ligand superfamily member 11 inhibitor
TNFSF11Phase 3Postmenopausal Women With Osteoporosis at High Risk of FractureJan 2027
QLM3003 ointment (1.5%)–Phase 3Atopic DermatitisMar 2027
MHB088C for Injection
Antibody drug conjugate (ADC)
–Phase 3Small Cell Lung Cancer Extensive Stage; Advanced/Metastatic Solid TumorsMay 2027
ESG401
Estrogen receptor degrader
–Phase 3Triple-Negative Breast Cancer (TNBC); Metastatic Breast CancerJun 2027
GM1
Monosialotetrahexosylganglioside (GM1 ganglioside)
–Phase 3Chemotherapy-induced Peripheral Neuropathy (CIPN); StrokeJun 2027
QLM3004 Ophthalmic Solution–Phase 3MyopiaJun 2027
Voclosporin (QL1074)
Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
PPP3CAPhase 3Lupus NephritisJun 2027
QL1706–Phase 3Carcinoma, Non-Small-Cell Lung; Lung Cancer; Colon Cancer; Advanced Solid Tumor …Aug 2027
QLS32015
Unclear - proprietary code-named compound
–Phase 3Relapsed or Refractory Multiple MyelomaNov 2027
QL2106 injection
IL-23 inhibitor
IL23APhase 3Plaque PsoriasisDec 2027
QLS31905
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic CancerSep 2028
QL0911–Phase 2Cancer Treatment-Induced ThrombocytopeniaApr 2027
QLC2519
Modified G-CSF fused to human serum albumin (HSA) with reduced G-CSF receptor affinity
CSF3RPhase 2Pediatric Malignant Solid TumorJun 2027
QLS1304
unclear - mechanism not specified in registry text
–Phase 1Advanced Malignant Tumor; Advanced ER+/HER2- Breast CancerNov 2026
QLH12016
Androgen receptor PROTAC
ARPhase 1Advanced Prostate CancerDec 2026
QLC1101
KRAS G12D inhibitor
KRASPhase 1Non-small Cell Lung CancerApr 2027
QLS31903–Phase 1Advanced Solid TumorsJun 2027
QLS5212
anti-trophoblast glycoprotein (TPBG) antibody-drug conjugate
TPBGPhase 1Solid Tumor CancerNov 2027
QLP2117–Phase 1Advanced Solid TumorDec 2027
QLS2309
anti-CD70 antibody-drug conjugate
CD70Phase 1Relapsed or Refractory Hematologic MalignanciesDec 2027
QLS2319–Phase 1Cancer CachexiaOct 2028
Follitropin Alfa
Follicle stimulating hormone receptor agonist
FSHRPhase 1Infertility, Female–
Meropenem-Pralubactam
Beta-lactam antibiotic combined with beta-lactamase inhibitor
–Phase 1Infections–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05320406RelugolixPhase 2Biochemically Recurrent Prostate CarcinomaOncologyJan 2025
NCT07124468Meropenem-PralubactamPhase 1InfectionsInfectious diseaseDec 2025
NCT07096310MeropenemPhase 1SepsisInfectious diseaseJan 2026
NCT06864793Follitropin AlfaPhase 1Infertility, FemaleGenitourinaryFeb 2026
NCT06631521RelugolixPhase 1Prostate CAOncologyJun 2026
NCT07694700MeropenemPhase 4MDR BacteriaOtherAug 2026
NCT06671548RelugolixPhase 3Heavy Menstrual BleedingGenitourinaryNov 2026
NCT06823609QLS1304Phase 1Advanced Malignant TumorOncologyNov 2026
NCT06787183QL1706Phase 2Locally Advanced Rectal Cancer With Liver MetastasesOncologyDec 2026
NCT06809530QL1706Phase 1Leptomeningeal MetastasisOncologyDec 2026
NCT07620041QLC5508Phase 1Refractory or Relapsed Solid TumorsOncologyDec 2026
NCT07198633QLC5508Phase 1Advanced Prostate CancerOncologyDec 2026
NCT06799559QLM1016Phase 3SchizophreniaPsychiatryDec 2026
NCT07089186MeropenemPhase 3Hospital-acquired Bacterial Pneumonia (HABP)Infectious diseaseDec 2026
NCT07198633QLH12016Phase 1Advanced Prostate CancerOncologyDec 2026
NCT06754644Pembrolizumab (QL2107)Phase 3NSCLCOncologyDec 2026
NCT07162883Pembrolizumab (QL2107)Phase 3Carcinoma, Non-Small-Cell LungOncologyDec 2026
NCT07062978Denosumab (QL1206)Phase 3Postmenopausal Women With Osteoporosis at High Risk of FractureMetabolic and endocrineJan 2027
NCT07519044GM1Phase 4StrokeNeurologyJan 2027
NCT06897046QL1706Phase 2Non-small Cell Lung Cancer (NSCLC)OncologyFeb 2027
NCT06880276QLM3003 ointment (1.5%)Phase 3Atopic DermatitisImmunologyMar 2027
NCT06880276QLM3003 ointment (1.5%)Phase 3Atopic DermatitisImmunologyMar 2027
NCT06941766QL1706Phase 1Intermediate Trophoblastic TumorOncologyApr 2027
NCT06456528QL0911Phase 2Cancer Treatment-Induced ThrombocytopeniaOncologyApr 2027
NCT06403735QLC1101Phase 1Non-small Cell Lung CancerOncologyApr 2027
NCT07014150QL1706Phase 2Hepatocellular Carcinoma ResectableOncologyMay 2027
NCT07014150QL1706Phase 2Hepatocellular Carcinoma ResectableOncologyMay 2027
NCT06954246MHB088C for InjectionPhase 3Small Cell Lung Cancer Extensive StageOncologyMay 2027
NCT06967103QL1706Phase 2Breast CancerOncologyMay 2027
NCT07302451RelugolixPhase 2Prostate Cancer (Adenocarcinoma)OncologyMay 2027
NCT05489523TafamidisPhase 4Transthyretin Cardiac AmyloidosisCardiovascularMay 2027
NCT06151587QLM3004 Ophthalmic SolutionPhase 3MyopiaOphthalmologyJun 2027
NCT06732323ESG401Phase 3Triple-Negative Breast Cancer (TNBC)OncologyJun 2027
NCT06406205Voclosporin (QL1074)Phase 3Lupus NephritisImmunologyJun 2027
NCT06994507GM1Phase 3Chemotherapy-induced Peripheral Neuropathy (CIPN)NeurologyJun 2027
NCT05823285QLS31903Phase 1Advanced Solid TumorsOncologyJun 2027
NCT07724756QLC2519Phase 2Pediatric Malignant Solid TumorOncologyJun 2027
NCT06313970QL1706Phase 2Pancreatic CancerOncologyJun 2027
NCT06383767ESG401Phase 3Metastatic Breast CancerOncologyJun 2027
NCT05765500RelugolixPhase 2Prostate CancerOncologyJul 2027
NCT07102004MHB088C for InjectionPhase 1Advanced/Metastatic Solid TumorsOncologyJul 2027
NCT07070700QL1706Phase 2Intrahepatic Cholangiocarcinoma (Icc)OncologyAug 2027
NCT07091305QL1706Phase 2Limited-stage Small Cell Lung Cancer (LS-SCLC)OncologyAug 2027
NCT07178171QL1706Phase 1TNBC, Triple Negative Breast CancerOncologyAug 2027
NCT07111247RelugolixPhase 4Cervical MucusOtherAug 2027
NCT05487391QL1706Phase 3Carcinoma, Non-Small-Cell LungOncologyAug 2027
NCT07180160QL1706Phase 2Advanced Breast CancerOncologySep 2027
NCT07467629QLS5212Phase 1Solid Tumor CancerOncologyNov 2027
NCT07018050QLS32015Phase 2Relapsed or Refractory Multiple MyelomaOncologyNov 2027
NCT07179900QL1706Phase 2Hepatocellular CarcinomaOncologyDec 2027
NCT06911827Pembrolizumab (QL2107)Phase 1Advanced Solid TumorOncologyDec 2027
NCT06911827QLP2117Phase 1Advanced Solid TumorOncologyDec 2027
NCT07138209QLS32015Phase 3Relapsed or Refractory Multiple MyelomaOncologyDec 2027
NCT07173595QLS2309Phase 1Relapsed or Refractory Hematologic MalignanciesOncologyDec 2027
NCT07511647QL2106 injectionPhase 3Plaque PsoriasisImmunologyDec 2027
NCT06330805RelugolixPhase 2Prostate AdenocarcinomaOncologyDec 2027
NCT06940336TafamidisPhase 4Transthyretin Amyloid PolyneuropathyNeurologyJan 2028
NCT07267078QL1706Phase 2Biliary Tract CancerOncologyJan 2028
NCT06111781RelugolixPhase 2Prostate CancerOncologyFeb 2028
NCT06293677MeropenemPhase 4Febrile NeutropeniaOncologyMar 2028

The 60 nearest readouts of 93 trials; the rest in the app.

Targets

B7H3 (1) FTSZ (1) AR (1) TNFSF11 (1) PDCD1 (1) FSHR (1) CSF3R (1) GNRHR (1) KRAS (1) CD70 (1) CLDN18 (1) PPP3CA (1)

Companies with the same targets

Akeso Johnson & Johnson (Janssen) AstraZeneca Basilea Pharmaceutica Novartis Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Hansoh BioMedical R&D Company

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.